Opinion|Videos|December 5, 2025
PCSK9 Inhibitor Underuse
Panelists discuss how PCSK9 inhibitors remain underused due to access, cost, and adherence barriers.
Advertisement
Episodes in this series
Panelists discuss how PCSK9 inhibitors remain underutilized despite their strong efficacy and safety record. The main barriers are cost, prior authorization requirements, and patient hesitancy with injectable formats.
They note that even eligible high-risk patients often abandon therapy due to administrative complexity or affordability.
Panelists call for streamlined access pathways and education to ensure these life-saving agents reach appropriate patients.
Advertisement
Related to this article
Pharmacists outline new oncologic therapeutics, from pancreatic cancer to myeloma, and what high prices and crowded markets mean for payers.
Invivyd presented preclinical IDWeek 2026 data on VMS063, an investigational antibody that neutralized B3 and D8 measles variants in vitro.
Sphingolipid profiles in plasma and breath condensate differed between IPF and f-HP and tracked with disease severity, CHEST 2026 data show.
The FDA granted accelerated approval to the first plasmid DNA-based immunotherapy for adults with recurrent respiratory papillomatosis (RRP).
October's FDA approvals included the introduction of 5 non-oncology treatment options across specialties.
A phase 4 study found 69% of patients with OAB were consistently satisfied with vibegron at 12 months, with exploratory persistence of 59.8%.
Advertisement
Advertisement
Trending on AJMC
1
First-Line Vitiligo Treatment: Topical JAK Inhibitors and Phototherapy
2
Precision Drugs Meet Payer Realities
3
Cleveland Clinicians Say Obesity Care Starts Too Late for Many Patients
4
GOLD COPD Conference Turns to Earlier Diagnosis and Proactive Care
5